Target intelligence / Profile preview

MicroRNA 320d (miR-320d)

Target
miR-320d
Molecular classification
MicroRNA, Non-coding RNA, Regulatory RNA, Other
01

Overview

MicroRNA 320d is a small, endogenous non-coding RNA of approximately 22 nucleotides, classified within the microRNA-320 family. It regulates target gene expression via post-transcriptional silencing, primarily binding complementary sequences in the 3′-UTR of specific mRNAs such as TUSC3, FoxM1, and CDK6, thereby preventing their translation and promoting mRNA degradation. miR-320d plays a vital role in cancer biology, functioning primarily as a tumor suppressor. Its expression is downregulated in multiple human malignancies, and restoration of miR-320d in cancer cells suppresses proliferation, migration, invasion, and EMT, largely by modulating PI3K/Akt/mTOR and associated pathways. miR-320d is under evaluation as a biomarker for prognosis and therapeutic response, but no miR-320d-targeted drugs are in clinical use. The "-2" designator has little precedent in research literature; miR-320d itself is the canonical and functionally relevant form.

Other names
miR-320dhsa-miR-320dmicroRNA-320dmember of the miRNA-320 family
02

Mechanism of action

Synthetic miR-320d mimics restore tumor-suppressive activity, downregulate TUSC3, CDK6, and FoxM1, inhibit PI3K/Akt/mTOR signaling, and block EMT. Antisense inhibitors block endogenous miR-320d effects, permitting overexpression of oncogenes.

03

Biological functions

Post-transcriptional gene regulationInhibition of cell proliferationSuppression of cell migration and invasionRegulation of epithelial-mesenchymal transition (EMT)Promotion of apoptosisRegulation of tumor suppressor and oncogene pathways (e.g., TUSC3, CDK6, FoxM1)
04

Disease associations

Cancer (colorectal cancer, gastric cardiac adenocarcinoma, diffuse large B-cell lymphoma, acute myeloid leukemia)Chemoradiotherapy sensitivity (predictive biomarker in rectal cancer)Infection (herpesvirus regulation)Other
05

Safety considerations

Off-target effects (typical of RNA-based therapy)Biological redundancy within the miRNA-320 familyUncertain long-term safety for systemic administration
06

Interacting drugs

Synthetic miR-320d mimics

1 more in the full profile.

07

Biomarkers

Serum/plasma miR-320d levels serve as a prognostic and predictive biomarker in colorectal and gastric adenocarcinomaDownregulation is associated with poor prognosis and advanced disease in various cancers

Beyond the preview

Go deeper on MicroRNA 320d (miR-320d).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 320d (miR-320d).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call